Survival and prognostic factors in adult medulloblastoma: the Salah Azaiz Institute experience
| Autor: | Lotfi Kochbati, S. Yahyaoui, R. Abidi, Alia Mousli, Asma Belaid, Chiraz Nasr, Dorra Aissaoui, Amal Boussarsar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Medulloblastoma
Oncology Chemotherapy medicine.medical_specialty Adult Medulloblastoma business.industry medicine.medical_treatment Malignant brain tumor General Medicine medicine.disease Radiation therapy 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Surgery Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | British Journal of Neurosurgery. :1-4 |
| ISSN: | 1360-046X 0268-8697 |
| Popis: | Medulloblastoma is the most common malignant brain tumor in children. This entity in adulthood is rare. The aim of our study is to evaluate therapeutic results and prognostic factors of adult medulloblastoma treated at our institute with post-operative radiotherapy.We retrospectively reviewed a cohort of 55 patients with medulloblastoma who underwent radiation in the department of radiation oncology of institute Salah Azaiz (Tunis) over a 18-year period (1994-2012).The surgery was total or subtotal resection in 73% of cases. Forty-eight patients received radiotherapy to the entire craniospinal axis as part of the curative treatment. The median interval from surgery to the initiation of radiotherapy was 83 days. Etoposide-cisplatin chemotherapy was only performed in metastatic patients (Our results, compared to those of the literature, conclude that the reduction in the dose of radiotherapy to the craniospinal axis (34 Gy) in the standard risk group of adult medulloblastoma could not be done without chemotherapy. In the high-risk group of adult medulloblastoma, radiotherapy to the cerebrospinal axis at the dose of 36 Gy with chemotherapy, is required for disease control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|